Skip to main content
. 2018 May 23;25(1):1224–1233. doi: 10.1080/10717544.2018.1469685

Figure 4.

Figure 4.

(A) CLSM images of ileum sections of the mice after oral administrations with Cy5-INS/RhB-HTCC-CA, Cy5-INS/RhB-HTCC/FITC-HPMCP, and Cy5-INS/RhB-HTCC-CA/FITC-HPMCP; the ileums were excised at 4 h post-administration. (B) Representative fluorescence images of the GI tracts excised at 0, 2, 6, and 12 h after oral administrations with Cy5-INS-loaded nanoparticles and (C) relative fluorescence intensity distributions of Cy5-INS/HTCC-CA/HPMCP in the GI tracts. (D) Representative fluorescence images of heart, liver, spleen, lung, and kidney excised at 0, 2, 6, 12 and 24 h after oral administrations with Cy5-INS loaded nanoparticles and (E) fluorescence intensities of liver after oral administrations with Cy5-INS loaded nanoparticles. The insulin dose was 30 IU/kg, n = 3, and *p < .05.